e-Dialog, Inc.

e-Dialog Recognized as One of Massachusetts' Fastest Growing Private Companies

e-Dialog Recognized as One of Massachusetts' Fastest Growing Private Companies

April 16, 2007

Boston Business Journal Names E-mail Service Provider as Regional Pacesetter

LEXINGTON, Mass., April 16, 2007 – e-Dialog, provider of advanced e-mail marketing services, today announced that it ranked No. 22 on the Boston Business Journal's list of the region's fastest growing private companies. The company was among 60 businesses honored during an event held on April 13th at the Park Plaza Hotel in Boston.

Mascoma Corporation

Mascoma Honored with Red Herring 100 Selection

Mascoma Honored with Red Herring 100 Selection

May 2, 2007

2007 Awards Recognize the 100 Most Promising Companies Driving the Future of Technology

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals Closes $53 Million in Series D Funding

AVEO Pharmaceuticals Closes $53 Million in Series D Funding

May 3, 2007

Cambridge, MA – May 3, 2007 – AVEO Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of novel, targeted cancer medicines, today announced that it has closed a $53 million Series D financing. Proceeds from this financing will be used to accelerate the development of AVEO’s pipeline of novel, clinical-stage cancer therapies.

Ensemble Therapeutics Corporation

Ensemble Evolves Name to Ensemble Therapeutics Corporation

Ensemble Evolves Name to Ensemble Therapeutics Corporation

June 22, 2010

Prompted by Progress in Developing New Therapeutic Modality: “Small Molecules with the Power of Biologics”
Ensemble also announces new strategic investor: Kisco Ltd.

Mr. Afeyan Goes to Washington

Mr. Afeyan Goes to Washington

June 21, 2010

MONDAY, JUNE 21, 2010 -- Flagship Managing Partner Noubar Afeyan was in Washington, D.C. today to accept a Presidential Green Chemistry Challenge Award on behalf of Flagship portfolio company LS9. Afeyan was a co-founder of the company in 2005, and serves on the Board of Directors.

Read an interview by Dan Primack with Afeyan following the ceremony on peHub.com -- Mr. Afeyan Goes to Washington.

Five Flagship Ventures Portfolio Companies Named Winners of Red Herring 100 Awards for 2007

Five Flagship Ventures Portfolio Companies Named Winners of Red Herring 100 Awards for 2007

May 8, 2007

CAMBRIDGE, Mass., May 8, 2007--(BUSINESS WIRE)--Flagship Ventures announced today that five companies from its portfolio of venture investments were named winners of the Red Herring 100 for 2007. Codon Devices, Interactive Supercomputing, Mascoma, Pervasis Therapeutics, and ZoomInfo were chosen from over 800 entries in the 10th annual competition. During the past decade, the Red Herring 100 has come to be an eagerly awaited list highlighting some of the most promising companies and entrepreneurs in the high tech and life science start-up world.

BG Medicine, Inc.

BG Medicine Forms Research Collaboration with M.D. Anderson Cancer Center to Discover Serum Biomarkers for Breast Cancer Treatment Response

BG Medicine Forms Research Collaboration with M.D. Anderson Cancer Center to Discover Serum Biomarkers for Breast Cancer Treatment Response

May 9, 2007

WALTHAM, Mass.--(BUSINESS WIRE)--BG Medicine announced today that it has entered into a research collaboration with The University of Texas M. D. Anderson Cancer Center aimed at improving the treatment of breast cancer. Under this agreement, BG Medicine will apply its biomarker discovery technology to the analysis of clinical samples provided by The University of Texas M. D. Anderson Cancer Center. The goal of the collaboration is to identify novel, specific and sensitive blood-based protein and metabolite biomarkers in breast cancer patients who are receiving selected treatments.

BG Medicine, Inc.

BG Medicine and Multiple Sclerosis Research Center of New York Announce Collaboration on Biomarker Discovery for MS Disease Activity and Drug Response

BG Medicine and Multiple Sclerosis Research Center of New York Announce Collaboration on Biomarker Discovery for MS Disease Activity and Drug Response

May 16, 2007

Biomarkers may lead to improved drug development and clinical patient management

BG Medicine, Inc.

BG Medicine Acquires Exclusive Rights to Biomarkers of Congestive Heart Failure from ACS Biomarker

BG Medicine Acquires Exclusive Rights to Biomarkers of Congestive Heart Failure from ACS Biomarker

May 23, 2007

BG Medicine plans to develop and commercialize molecular diagnostic tests for the prognosis of patients with congestive heart failure

Helicos BioSciences Corporation

Helicos Biosciences Prices Initial Public Offering

Helicos Biosciences Prices Initial Public Offering

May 24, 2007

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Helicos BioSciences Corporation (Nasdaq: HLCS) announced today that it has priced its initial public offering of 5,400,000 shares of common stock at $9.00 per share. All of the common stock is being offered by the company, and the common stock will trade on the NASDAQ Global Market under the symbol "HLCS." The company has granted the underwriters an option to purchase up to an additional 810,000 shares to cover over-allotments, if any.